Komori
Mitsubishi Chemical Group (4188) · InitiativeAdvanced

Expansion into diabetes treatment through a Japanese commercialization partnership for Mounjaro

First written in FY2023-Q2. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q2 – FY2023AdvancedFY2025-H1 – FY20252022: 120222023: 120232024: 120242025: 12025
Same theme, other companies
Sales partnership for Mounjaro and Zepbound in JapanA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「Eli Lilly Japan K.K. obtained Japanese marketing approval in December 2024 for Zepbound®, a long-acting GIP/GLP-1 receptor agonist, for the indication of obesity, and began sales in April 2025. As with Mounjaro®, the same molecule marketed in Japan by both companies as a treatment for type 2 diabetes, 田辺三菱製薬 will distribute and sell Zepbound® in Japan, while Eli Lilly Japan K.K. and 田辺三菱製薬 will jointly provide information on the product.」

    Following Mounjaro, the approval and launch in Japan of Zepbound, an obesity treatment based on the same molecule, and the two companies' distribution, sales and information-provision arrangements were specified.
  2. FY2025-H1AdvancedAnnual report

    「In pharmaceuticals, both revenue and core operating profit increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to growth in RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States, and foreign exchange effects; growth in Mounjaro, a long-acting GIP/GLP-1 receptor agonist, and influenza vaccines; and the smooth launch of Govic® aqueous suspension for injection, a combined adsorbed, purified pertussis, diphtheria, tetanus, inactivated polio and Haemophilus influenzae type b vaccine.」

    For the Pharma business, including the Japanese commercialization partnership for Mounjaro, growth in Mounjaro sales was identified as a factor contributing to increases in revenue and core operating profit during the interim period.
  3. FY2023RestatedAnnual report

    「In July 2022, we entered into a Japanese commercialization partnership agreement with Eli Lilly Japan K.K. for Mounjaro, the world's first long-acting GIP/GLP-1 receptor agonist.」

    The Japanese commercialization partnership for Mounjaro and the marketing approval obtained in September 2022 were reiterated as initiatives in the healthcare business for the fiscal year.
  4. FY2023-Q2First statedAnnual report

    「In July 2022, the company signed an agreement with Eli Lilly Japan K.K. (headquartered in Kobe, Hyogo Prefecture) to co-promote Mounjaro, the world's first long-acting GIP/GLP-1 receptor agonist, in Japan. Eli Lilly Japan obtained marketing approval in Japan for the product in September of the same year, with type 2 diabetes as its indication.」

    田辺三菱製薬 entered into a Japanese commercialization partnership agreement with Eli Lilly Japan for Mounjaro, a long-acting GIP/GLP-1 receptor agonist, and progressed to obtaining Japanese marketing approval in September of the same year.
Moved together

"Portfolio and Structural Reform of the Petrochemicals Business" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Portfolio and Structural Reform of the Petrochemicals Business2×
  3. 2Improving profitability through cost reductions and asset reduction2×
  4. 3Building an Australia and Oceania platform through the acquisition of an industrial-gases business2×
  5. 4Funding risks from interest-bearing debt, interest rates and credit-rating downgrades2×
  6. 5Strategic investments, including capital expenditure and M&A, in growth businesses2×
  7. 6Circular Economy and Climate Change Measures Looking Toward 2050 and 20302×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.